Показано 0 из 0
Дата |
---|
20:00 |
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.10
|
1.16
|
1.09
|
1.09
|
1.25
|
1.145
|
|
|
44 841.85
|
128.00
|
0.8553
|
1.12
|
1.06
|
1.0246
|
1.12
|
1.09
|
|
|
7 665.70
|
95.00
|
1.05
|
1.11
|
1.01
|
1.01
|
1.11
|
1.10
|
|
|
21 563.99
|
325.00
|
1.00
|
1.03
|
0.9618
|
0.915
|
1.05
|
1.05
|
|
|
40 762.10
|
179.00
|
0.825
|
0.9109
|
0.9479
|
0.85
|
0.97
|
0.93
|
|
|
22 159.44
|
135.00
|
0.93
|
0.98
|
0.93
|
0.92
|
0.98
|
0.92
|
|
|
9 583.52
|
54.00
|
0.92
|
1.01
|
0.955
|
0.93
|
0.955
|
0.93
|
|
|
3 515.81
|
88.00
|
0.825
|
0.99
|
0.885
|
0.822101
|
0.99
|
0.9361
|
|
|
9 207.69
|
99.00
|
0.88
|
0.98
|
0.915
|
0.91
|
0.969
|
0.9408
|
|
|
17 277.32
|
102.00
|
0.88
|
1.00
|
0.849
|
0.8274
|
0.94
|
0.88
|
|
|
3 184.36
|
101.00
|
Estrella Immunopharma, Inc. operates as a preclinical-stage biopharmaceutical company. The Company focuses on developing CD19 and CD22-targeted T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella Immunopharma serves customers worldwide.